Barclays Downgrades Janux Therapeutics to Underweight, Lowers Price Target to $14

Benzinga Newsdesk www.benzinga.com Negative 94.1%

Neg 94.1% Neu 0% Pos 0%

Barclays analyst Etzer Darout downgrades Janux Therapeutics (NASDAQ:JANX) from Overweight to Underweight and lowers the price target from $29 to $14.